Results 61 to 70 of about 3,459,561 (335)
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors.
, 2008 Contains fulltext : 71063.pdf (Publisher’s version ) (Open Access)BACKGROUND: The last decade has seen the introduction of renin inhibitors and new plasma renin and prorenin assays, which has led to a better understanding of the tissue ...
Deinum, J. +3 more
core +2 more sources
The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism
Frontiers in Pharmacology, 2021 Primary aldosteronism (PA) is a potentially curable form of secondary hypertension caused by excessive renin-independent aldosterone secretion, leading to increased target organ damage and cardiovascular morbidity and mortality.
Piotr Jędrusik +3 more
doaj +1 more source
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
British Journal of Clinical Pharmacology, EarlyView.Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction [PDF]
, 2019 Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific ...
Savarese, G, +3 more
core +1 more source
Journal of Pharmacological Sciences, 2010 The role of angiotensin II in mediating hypertension and renal diseases is well documented, and inhibition of the renin–angiotensin–aldosterone system elicits antihypertensive and renoprotective effects.
Akira Nishiyama +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen +8 more
wiley +1 more source
Renin as a target of direct pharmacological block in arterial hypertension
Терапевтический архив, 2009 Renin is a basic component of renin-angiotensin-aldosteron system which contributes much to the activity of this system. Renin and its precursor prorenin can interact with prorenin receptors thus inducing hypertrophy and fibrogenesis in target tissues ...
Nikolay Alekseevich Mukhin +3 more
doaj
Chronic Diseases and Translational Medicine, EarlyView.Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian +4 more
wiley +1 more source
, 2023 Background The evidence supporting the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and beta-blockers for the prevention of anthracycline-induced cardiomyopathy is controversial.
Monica Samuel Avila (10376043) +6 more
core +1 more source